CN114286822A - 作为pd-1/pd-l1小分子抑制剂的化合物及其应用 - Google Patents

作为pd-1/pd-l1小分子抑制剂的化合物及其应用 Download PDF

Info

Publication number
CN114286822A
CN114286822A CN202080060528.1A CN202080060528A CN114286822A CN 114286822 A CN114286822 A CN 114286822A CN 202080060528 A CN202080060528 A CN 202080060528A CN 114286822 A CN114286822 A CN 114286822A
Authority
CN
China
Prior art keywords
compound
alkyl
reaction
mmol
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080060528.1A
Other languages
English (en)
Inventor
吴凌云
王才林
徐雄彬
童海骏
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN114286822A publication Critical patent/CN114286822A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

一类联芳基的化合物，具体公开了式(Ⅰ)所示化合物及其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN202080060528.1A 2019-09-30 2020-09-30 作为pd-1/pd-l1小分子抑制剂的化合物及其应用 Pending CN114286822A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910943193 2019-09-30
CN2019109431937 2019-09-30
CN2020109118822 2020-09-02
CN202010911882 2020-09-02
PCT/CN2020/119511 WO2021063404A1 (zh) 2019-09-30 2020-09-30 作为pd-1/pd-l1小分子抑制剂的化合物及其应用

Publications (1)

Publication Number Publication Date
CN114286822A true CN114286822A (zh) 2022-04-05

Family

ID=75336773

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080060528.1A Pending CN114286822A (zh) 2019-09-30 2020-09-30 作为pd-1/pd-l1小分子抑制剂的化合物及其应用

Country Status (8)

Country Link
US (1) US20220402917A1 (zh)
EP (1) EP4043461A1 (zh)
JP (1) JP2022550427A (zh)
KR (1) KR20220059517A (zh)
CN (1) CN114286822A (zh)
AU (1) AU2020357529A1 (zh)
CA (1) CA3152690A1 (zh)
WO (1) WO2021063404A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116710460A (zh) * 2021-01-18 2023-09-05 上海齐鲁制药研究中心有限公司 联苯衍生物及其应用
TW202241893A (zh) * 2021-03-30 2022-11-01 大陸商南京明德新藥研發有限公司 四氫萘啶化合物晶型、鹽型及其製備方法
US20230131465A1 (en) * 2021-09-14 2023-04-27 Boehringer Ingelheim International Gmbh 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament
WO2024018403A1 (en) * 2022-07-21 2024-01-25 Arbutus Biopharma Corporation Substituted imidazoamide compounds, and methods using same
CN117343006A (zh) * 2023-10-08 2024-01-05 河南科技大学 一种arb-272572的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119224A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
CN111936475A (zh) * 2018-04-03 2020-11-13 贝达药业股份有限公司 免疫调节剂及其组合物和制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016002544A (es) 2013-09-04 2016-06-17 Squibb Bristol Myers Co Compuestos utiles como inmunomoduladores.
PL3041827T3 (pl) 2013-09-06 2018-09-28 Aurigene Discovery Tech Limited Pochodne 1,2,4-oksadiazolu jako immunomodulatory
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
EP4141002A1 (en) * 2015-11-19 2023-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
MA44075A (fr) * 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
ES2899402T3 (es) * 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2019087087A1 (en) 2017-11-03 2019-05-09 Aurigene Discovery Technologies Limited Dual inhibitors of tim-3 and pd-1 pathways
UA126458C2 (uk) 2018-02-13 2022-10-05 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119224A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
CN111936475A (zh) * 2018-04-03 2020-11-13 贝达药业股份有限公司 免疫调节剂及其组合物和制备方法

Also Published As

Publication number Publication date
US20220402917A1 (en) 2022-12-22
KR20220059517A (ko) 2022-05-10
EP4043461A1 (en) 2022-08-17
JP2022550427A (ja) 2022-12-01
WO2021063404A1 (zh) 2021-04-08
AU2020357529A1 (en) 2022-05-19
CA3152690A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
CN114286822A (zh) 作为pd-1/pd-l1小分子抑制剂的化合物及其应用
JP5806438B1 (ja) １，３−ベンゾジオキソール誘導体
JP2023517995A (ja) ピリミドヘテロ環式化合物およびその応用
EP3833662B1 (en) Inhibitors of keap1-nrf2 protein-protein interaction
EP3848367A1 (en) Tricyclic compounds acting on crbn proteins
AU2016311426A1 (en) Compounds and compositions useful for treating disorders related to NTRK
TW201938556A (zh) 化合物及它們在治療癌症中之用途
JP2022141851A (ja) ブルトン型チロシンキナーゼの阻害剤及びその使用方法
CN112689638A (zh) 作为lsd1抑制剂的环丙胺类化合物及其应用
JP2022514437A (ja) 治療用化合物
CN117295727A (zh) 作为parp7抑制剂的哒嗪酮类化合物
KR20230142745A (ko) Cdk2 억제제 및 그의 사용 방법
JP2021501778A (ja) ｍＴＯＲＣ１／２二重阻害剤としてのピリドピリミジン系化合物
AU2022215616A1 (en) Quinoxaline derivatives and uses thereof
CN116390922A (zh) 硒杂环类化合物及其应用
TW202140499A (zh) 巨環ｒｉｐ２－激酶抑制劑
CN116981660A (zh) 氟代乙烯基联苯衍生物及其应用
WO2024046221A1 (en) Egfr inhibitors and uses thereof
WO2024015262A1 (en) Fused ring kras inhibitors for treating disease
TW202340198A (zh) 靶向ｍａｌｔ１的蛋白降解化合物、包含其的醫藥組合物及其用途
CN116438183A (zh) 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068189

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20230627

Address after: 201203 Building 1, No. 56 Faraday Road and 576 Libing Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai

Applicant after: Shanghai Qilu Pharmaceutical Research Center Co.,Ltd.

Address before: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

TA01 Transfer of patent application right